In particular, ado-trastuzumab emtansine (T-DM1), an ADC targeting the human epidermal growth factor receptor 2 (HER2), was the first compound approved for the treatment of trastuzumab-resistant metastatic BC in 2013 [7]. This evidence concerns the gene ERBB2 and breast cancer.